An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy
Rheumatoid Arthritis
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis
Eligibility Criteria
Inclusion Criteria: RA for at least 1 year Clear clinical signs of active RA in 1 knee joint Meet ARA (1987) criteria for diagnosis of RA and ACR (1991) criteria for RA functional classes I, II, or III Inadequate clinical response to a minimum of 3 months of therapy with anti-TNF-blocking agents Taking background DMARDs for a minimum of 3 months and at stable doses for at least 28 days Exclusion Criteria: Serious bacterial infection in last 3 months History of TB History of cancer within 5 years Evidence of latent or active bacterial or viral infection Intra-articular corticosteroids within 3 months Exposure to live vaccines Exposure to CTLA4Ig or BMS-188667 Treatment with immunoadsorption column(s), mycophenolate mofetil, leflunomide, anakinra, cyclosporine, etanercept, adalimumab, infliximab, azathioprine, oral or parenteral gold, D-penacillamine, calcineurin inhibitors, cyclophosphamide or other alkylating agents
Sites / Locations
- Local Institution
Arms of the Study
Arm 1
Experimental
1